Approved indications: Livmarli is FDA-approved to treat cholestatic pruritus in (1) patients 3 months of age and older with Alagille syndrome (ALGS) and (2) patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC). It is not recommended in certain PFIC type 2 patients who have specific ABCB11 variants that cause a nonfunctional or absent bile salt export pump.

Off-label and investigational uses: Maralixibat has been studied for cholestatic pruritus in other liver diseases such as primary biliary cholangitis and broader cholestatic liver disease, with mixed but generally encouraging phase 2 data, and a phase 3 trial (EXPAND) is ongoing in various cholestatic conditions. Outside of ALGS and PFIC, any use is off-label and typically reserved for specialist centers with close monitoring.

Efficacy expectations and time course:

• In clinical trials, many children with ALGS or PFIC had a clinically meaningful reduction in itch scores (often at least a 1‑point drop on standardized 0–4 itch scales), and some achieved near-complete relief.
• Improvements in itch can begin within about 2 weeks in some patients, with further gains over months; reductions in serum bile acids often parallel symptom improvement.
• Benefits on itch, sleep, and quality of life have been sustained over years in extension studies for many patients, though not everyone responds and some may lose response or stop due to side effects.
• Compared with traditional antipruritic drugs (such as antihistamines or rifampin) and surgical bile diversion, Livmarli directly targets bile acid recycling and offers a non-surgical option; compared with other IBAT inhibitors (like odevixibat), it has a similar mechanism but no head‑to‑head trials, so choice is usually based on age, specific diagnosis, and clinician experience.

Formulations and route: Livmarli is taken by mouth as an oral solution (9.5 mg/mL for Alagille syndrome; 19 mg/mL for PFIC) or as oral tablets for patients weighing at least 25 kg who can swallow tablets. The two solution strengths must not be interchanged when treating PFIC.

How to take it: Livmarli is taken on an empty stomach, about 30 minutes before a meal. For Alagille syndrome it is usually given once daily in the morning; for PFIC it is titrated to twice daily (morning and evening). The provided oral dosing dispenser (syringe) must be used to measure each dose, and household spoons should not be used. Tablets should generally be swallowed whole with water.

Typical dosing for Alagille syndrome (ALGS): Dosing is weight‑based. Treatment usually starts at 190 mcg/kg by mouth once daily for 1 week, then increases to 380 mcg/kg once daily as tolerated, not exceeding 28.5 mg (3 mL) per day with the oral solution or 30 mg per day with tablets. The prescriber calculates the exact volume or tablet strength based on the child’s weight and may adjust the dose for side effects.

Typical dosing for PFIC: For PFIC, Livmarli is given using the 19 mg/mL oral solution or tablets at higher, stepwise doses. It usually starts at 285 mcg/kg once daily in the morning, then is titrated as tolerated to 285 mcg/kg twice daily, then 428 mcg/kg twice daily, and finally up to 570 mcg/kg twice daily (the usual target), with a maximum daily dose of 38 mg per day for oral solution and 40 mg per day for tablets. Dose adjustments or slower titration may be needed if side effects occur.

Special dosing instructions: Do not open more than one bottle of oral solution at a time, and start a new dosing device with each new bottle. For young children, caregivers should gently squirt the solution into the side of the cheek rather than the back of the throat. The prescriber may lower the dose, pause treatment, or stop it permanently if there are significant liver test abnormalities, severe diarrhea, bleeding, or signs of vitamin deficiency or propylene glycol toxicity.

Missed dose guidance: For once‑daily dosing (ALGS), if a dose is missed and it is within 12 hours of the usual time, the missed dose can be taken as soon as remembered, then the regular schedule resumed; if more than 12 hours have passed, skip the dose and take the next dose at the usual time. For twice‑daily dosing (PFIC), if a dose is missed and it is within 6 hours of the usual time, it can be taken then, and the regular schedule resumed; if more than 6 hours have passed, skip the missed dose and take the next scheduled dose. Do not double doses to “catch up.”

Overdose: Ingestion of more than the prescribed amount can increase the risk of severe diarrhea, vomiting, dehydration, marked liver test abnormalities, or propylene glycol toxicity (especially in children under 5 years). Emergency medical evaluation or contact with a poison control center is recommended immediately if a substantial overdose is suspected or if symptoms such as extreme sleepiness, confusion, reduced urination, or collapse occur.

Common side effects: The most frequently reported side effects are diarrhea, abdominal (stomach) pain, vomiting, liver test abnormalities, fat‑soluble vitamin (A, D, E, K) deficiency, and bone fractures; in PFIC, rectal bleeding/hematochezia is also seen. These effects are very common, often start early in treatment, and are usually mild to moderate, but diarrhea and abdominal pain can occasionally be severe or lead to dehydration.

Serious or rare adverse effects:

• Liver injury and hepatic decompensation: Livmarli can worsen liver tests and, rarely, cause drug-induced liver injury; in PFIC trials, some patients developed hepatic decompensation, with a few requiring transplant and one reported death.
• Severe gastrointestinal events: Persistent or bloody diarrhea, severe abdominal pain, vomiting, or signs of dehydration require prompt medical attention and possible dose reduction or interruption.
• Fat-soluble vitamin deficiency complications: Worsening deficiency can lead to bone fractures, poor bone mineralization, or bleeding due to low vitamin K, especially without adequate supplementation.
• Propylene glycol toxicity: The oral solution contains propylene glycol; high exposures, particularly in children under 5 years or those with impaired kidney or liver function, can cause serious neurologic, kidney, or metabolic problems and require immediate evaluation.
• Allergic reactions: Though uncommon, serious hypersensitivity (trouble breathing, swelling of face or throat, hives) can occur and requires emergency care.

Warnings and precautions: Livmarli is contraindicated in patients with prior or active hepatic decompensation events (such as variceal bleeding, ascites, or hepatic encephalopathy). Baseline and periodic liver function tests (ALT, AST, bilirubin, INR) are recommended, especially during the first several months and after dose changes. Fat‑soluble vitamin levels should be checked and supplemented as needed. Extra caution and monitoring are advised in young children (because of propylene glycol), in those with significant portal hypertension, and in patients with kidney or additional liver disease.

Pregnancy, breastfeeding, and age considerations: Systemic absorption of maralixibat is low, so fetal and breastmilk exposure is expected to be minimal, but human data are limited; decisions in pregnancy or lactation should balance potential benefits in severe pruritus against limited experience and the need to maintain adequate maternal fat‑soluble vitamin levels. Safety and effectiveness have been established in the approved pediatric age ranges; use in older adults (≥65 years) has not been well studied.

Comparative safety: As a minimally absorbed IBAT inhibitor, Livmarli’s safety issues are driven mainly by effects in the gut (diarrhea, abdominal pain) and on bile acid and vitamin handling (liver tests, FSV deficiency), similar to other IBAT inhibitors. Unlike many systemic drugs, classic systemic toxicities are uncommon, but careful liver and nutritional monitoring is essential.

Reporting side effects and safety updates: Side effects should be reported to the prescribing clinician and can also be reported to the FDA’s MedWatch program or to the manufacturer’s patient-support line. Updated safety information is provided in the full Prescribing Information and on official Livmarli professional and patient websites.

Key drug–drug interactions: Bile acid binding resins (such as cholestyramine, colestipol, or colesevelam) can bind maralixibat and reduce its effect, so Livmarli should be taken at least 4 hours before or 4 hours after these medicines. Livmarli can inhibit the intestinal transporter OATP2B1 and may reduce absorption of OATP2B1 substrates (for example, many statins and some other oral drugs); clinicians may monitor their effects or levels and adjust doses if needed.

Other medicines, supplements, and foods: Because Livmarli can cause diarrhea, it may affect absorption of other oral medications with a narrow therapeutic window; prescribers may pay extra attention to drugs like certain anticoagulants, antiepileptics, or immunosuppressants. No specific food or beverage is contraindicated, but Livmarli should consistently be taken 30 minutes before meals. The effect of alcohol is not well studied; in patients with underlying liver disease, alcohol is generally discouraged.

Conditions and co-medications that require caution: Livmarli must not be used in patients with prior or active hepatic decompensation (such as variceal bleeding, ascites, or hepatic encephalopathy). Extra caution is needed in patients with advanced portal hypertension, other serious liver diseases, or kidney impairment, particularly young children receiving the oral solution because of propylene glycol. Use should be carefully weighed in pregnancy and breastfeeding, with attention to maintaining adequate fat‑soluble vitamin levels and monitoring maternal liver function.

Monitoring requirements: Before and during treatment, clinicians typically monitor liver tests (ALT, AST, bilirubin, INR), fat‑soluble vitamin levels, growth, and signs of bone health (fractures) or bleeding. In children under 5 years, careful monitoring for signs of propylene glycol toxicity (neurologic changes, metabolic or kidney abnormalities) is recommended. For patients on interacting medications such as statins or bile acid sequestrants, additional clinical or laboratory monitoring may be needed.

Diagnostic and procedure considerations: No specific interactions with imaging contrast or anesthetic agents are known, but because patients often have significant liver disease, anesthesia and procedures should be planned with liver status and bleeding risk (including vitamin K status) in mind.

Q: What is Livmarli and what is it used for?
A: Livmarli (maralixibat) is an oral medicine that blocks bile acid recycling in the intestine and is used to treat cholestatic itching in people 3 months and older with Alagille syndrome and 12 months and older with PFIC.

Q: How long does it take for Livmarli to improve itching?
A: Some patients notice less itching within about 2 weeks, but for many it takes several weeks to months to see full benefit, and not everyone responds.

Q: How should Livmarli be given to a child?
A: The dose is based on weight and is measured using the supplied oral syringe; it is given by mouth 30 minutes before a meal (once each morning for Alagille syndrome, or usually twice a day for PFIC), and tablets may be used instead of solution in children who weigh at least 25 kg and can swallow pills.

Q: What side effects should parents or caregivers watch for?
A: The most common problems are diarrhea, stomach pain, vomiting, abnormal liver tests, signs of fat‑soluble vitamin deficiency (such as bone pain, fractures, or easy bruising), and, in PFIC, possible rectal bleeding; any severe or persistent symptoms, yellowing of the eyes or skin, or unusual sleepiness or confusion should be reported right away.

Q: Can Livmarli be taken with other medicines for liver disease or cholesterol?
A: It can often be used with other treatments, but bile acid binding resins must be spaced at least 4 hours apart from Livmarli, and medicines that rely on the OATP2B1 transporter (such as many statins) may need closer monitoring or dose adjustments.

Q: Will my child need blood tests while on Livmarli?
A: Yes, regular blood tests are usually done to check liver function and fat‑soluble vitamin levels, and the dose may be adjusted based on these results and how well the medicine is tolerated.

Storage: Store unopened Livmarli oral solution and tablets at room temperature, about 68°F to 77°F (20°C to 25°C), with short excursions between 59°F and 86°F (15°C to 30°C) allowed. After first opening the oral solution bottle, keep it below 86°F (30°C), tightly capped, and discard any remaining solution 100 days after opening. Keep all forms in the original child-resistant container and out of the reach of children.

Handling and measuring: Use only the dosing dispenser (oral syringe) that comes with the medicine to measure each dose; do not use household teaspoons or tablespoons. Do not open more than one bottle of oral solution at a time, and start a new dosing dispenser with each new bottle.

Disposal: When a bottle is expired or 100 days past first opening, mix any leftover solution with an unappealing substance (such as coffee grounds, cat litter, or dirt), place the mixture in a sealed bag or container, remove or mark out personal information on the bottle label, and throw the sealed container and empty bottle into the household trash according to local guidance. Used oral dosing dispensers can also be thrown away in household trash unless local rules advise otherwise.